<DOC>
	<DOCNO>NCT00266877</DOCNO>
	<brief_summary>The purpose study learn whether HKI-272 safe effective treat non-small cell lung cancer .</brief_summary>
	<brief_title>Study Evaluating Safety Of HKI-272 ( Neratinib ) In Subjects With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Pathologic diagnosis NSCLC current stage IIIB ( pleural effusion ) IV , curable conventional therapy . For Arm C , less equal 20 packyears smoke history current non smoker . A pack year = number pack cigarettes smoked per day x year smoke . Progression follow least 12 week treatment Tarceva Iressa . ( Arms A B ) ECOG ( Eastern Cooperative Oncology Group ) performance status 0 , 1 , 2 ( decline within past 2 week ) . Tumor sample available adequate analysis . At least one measurable target lesion . Adequate cardiac , kidney , liver function Adequate blood count More 3 prior cytotoxic chemotherapy treatment relapse metastatic disease . Significant cardiac disease dysfunction . Prior treatment anthracyclines cumulative dose &gt; 400 mg/m^2 . Active central nervous system metastasis , indicate clinical symptom and/or progressive growth . Use Tarceva Iressa within 14 day treatment day 1 ( Arms A B ) . Major surgery , chemotherapy , radiotherapy , investigational drug , cancer therapy within 3 week treatment day 1 . Significant chronic recent acute gastrointestinal disorder diarrhea major symptom . Inability unwillingness swallow HKI272 capsule . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Lung Cancer</keyword>
</DOC>